Literature DB >> 8878596

In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.

K V Singh1, T M Coque, B E Murray.   

Abstract

The in vitro activity of the trinem sanfetrinem (formerly GV104326) (GV) was compared with that of vancomycin, ampicillin, and/or nafcillin against 287 gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and multiresistant enterococci, by the agar and microbroth dilution methods. GV demonstrated 2 to 16 times more activity than ampicillin and nafcillin against the majority of these organisms. The MIC range of GV was 16 to 64 micrograms/ml for 19 Enterococcus faecium strains that were highly resistant to ampicillin (ampicillin MIC range, 64 to 512 micrograms/ml) and vancomycin resistant and 0.25 to 32 micrograms/ml for resistant Rhodococcus spp. Similar activities (+/-1 dilution) were observed by either the agar or the broth microdilution method. GV demonstrated bactericidal activity against a beta-lactamase-producing Enterococcus faecalis strain and against two methicillin-susceptible Staphylococcus aureus strains in 10(5)-CFU/ml inocula. Synergy between GV and gentamicin was observed against an E. faecalis strain that lacked high-level gentamicin resistance. The activity of GV suggests this compound warrants further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878596      PMCID: PMC163488     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Beta-lactamase-producing enterococci.

Authors:  B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.

Authors:  E Di Modugno; I Erbetti; L Ferrari; G Galassi; S M Hammond; L Xerri
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

3.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

4.  Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  J Bacteriol       Date:  1984-05       Impact factor: 3.490

5.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.

Authors:  S Handwerger; B Raucher; D Altarac; J Monka; S Marchione; K V Singh; B E Murray; J Wolff; B Walters
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

6.  Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.

Authors:  F Soriano; J Zapardiel; E Nieto
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.

Authors:  M A Montecalvo; H Horowitz; C Gedris; C Carbonaro; F C Tenover; A Issah; P Cook; G P Wormser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Correlation between antibiotic resistance, phage-like particle presence, and virulence in Rhodococcus equi human isolates.

Authors:  P Nordmann; M Keller; F Espinasse; E Ronco
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

9.  Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium.

Authors:  R Fontana; M Aldegheri; M Ligozzi; H Lopez; A Sucari; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus.

Authors:  H Hanaki; H Akagi; Y Masaru; T Otani; A Hyodo; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  8 in total

1.  Electrostatic and structural similarity of classical and non-classical lactam compounds.

Authors:  M Coll; J Frau; B Vilanova; J Donoso; F Muñoz
Journal:  J Comput Aided Mol Des       Date:  2001-09       Impact factor: 3.686

2.  In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.

Authors:  Susanne Paukner; Lars Hesse; Andrej Prezelj; Tomaz Solmajer; Uros Urleb
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae.

Authors:  F Sifaoui; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States.

Authors:  Jessica R Galloway-Peña; Sreedhar R Nallapareddy; Cesar A Arias; George M Eliopoulos; Barbara E Murray
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

Review 6.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

7.  In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.

Authors:  S Tamura; S Miyazaki; K Tateda; A Ohno; Y Ishii; T Matsumoto; N Furuya; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

8.  Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae.

Authors:  A M Cuffini; V Tullio; A Bonino; A Allocco; A I Palarchio; N A Carlone
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.